Oral sirolimus

DRUG4 trials

Sponsors

Gifu university, Kyushu University Hospital, Centro de estudios en Cardiologia Intervencionista, Children's Hospital of Fudan University

Conditions

Coronary Heart DiseaseCoronary RestenosisKaposiform HemangioendotheliomaLymphangiomatosis, Gorham-Stout disease and vascular anomaliesRefractory lymphangiomatosis, Gorham-Stout diseaseSuperficial Lymphatic MalformationsSuperficial Vascular AnomaliesTufted Angioma

Phase 1

Sirolimus for the treatment of lymphangiomatosis, Gorham-Stout disease and vascular anomalies

Active, not recruitingJPRN-UMIN000016580

Gifu universityLymphangiomatosis, Gorham-Stout disease and vascular anomalies

Start: 2015-02-01Target: 30Updated: 2026-06-29

Phase 4

Study of Oral Rapamycin Plus Bare Metal Stents vs Drug Eltuting Stents

CompletedNCT00552669

Centro de estudios en Cardiologia IntervencionistaCoronary Heart Disease, Coronary Restenosis

Start: 2006-01-31End: 2007-09-30Updated: 2010-06-02

Percutaneous Administration of Sirolimus in the Treatment of Superficial Complicated Vascular Anomalies

RecruitingNCT04921722

Children's Hospital of Fudan UniversityKaposiform Hemangioendothelioma, Superficial Lymphatic Malformations, Superficial Vascular Anomalies +1

Start: 2021-10-22End: 2025-11-01Target: 75Updated: 2024-03-15

Unknown Phase

Sirolimus for the treatment of refractory lymphangiomatosis/ Gorham Stout disease

Active, not recruitingJPRN-UMIN000029843

Kyushu University HospitalRefractory lymphangiomatosis, Gorham-Stout disease

Start: 2017-08-04Target: 2Updated: 2026-06-29

Related Papers

The impact of sirolimus therapy on lesion size, clinical symptoms, and quality of life of patients with lymphatic anomalies.

2019-06-1374 citations